Drug Trial Radar · NCT07298330
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jan 14, 2026
Primary completion
Aug 2026
Study completion Jan 2029
Sponsor
- Lead sponsor
- Mirum Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, global, randomized, open-label, multicenter trial designed to evaluate the safety and efficacy of chronic treatment with brelovitug (BJT-778) for chronic hepatitis delta virus (HDV) infection. The objective of this study is to test the safety and effectiveness of brelovitug compared to delayed treatment.
Conditions
- Chronic Hepatitis D Infection
Interventions
Brelovitug 300 mgDrug
Route of administration- Subcutaneous Injection
Brelovitug 900 mgDrug
Route of administration- Subcutaneous Injection
Delayed Treatment with Brelovitug 300mgDrug
Route of administration- Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with a composite endpoint of virologic response and ALT normalization at Week 24 in brelovitug arms compared to response at Week 12 of delayed-treatment armTime frame: Week 24
Locations
27 sites in 10 countries. Site status is shown where the registry gives one.
University of California, Davis
Davis, California
Kaiser Permanente Medical Center
Sacramento, California
Quest Clinical Research
San Francisco, California
Denver Health Medical Center
Denver, Colorado
Alliance Clinical, Las Vegas
Las Vegas, Nevada
Cleveland Clinic
Cleveland, Ohio
Prime Clinical Research Inc
Mansfield, Texas
University of Utah
Salt Lake City, Utah
Erasme Hospital
Brussels, Belgium
University Hospital Antwerp (UZA)
Edegem, Belgium
University Hospital Center Sart-Tilman
Liège, Belgium
Acibadem City Clinic University Multiprofile Hospital for Active Treatment Tokuda
Sofia, Bulgaria
Hospital Service LTD
Kutaisi, Georgia
Diakori LLC
Tbilisi, Georgia
JSC T. Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center
Tbilisi, Georgia
LTD Academician Vakhtang Bochorishvili Clinic
Tbilisi, Georgia
Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases
Budapest, Hungary
Fejer County St. Gyorgy University Teaching Hospital
Székesfehérvár, Hungary
Soroka University Medical Center
Beersheba, Israel
HaEmek Medical Center
Haifa, Israel
Aga Khan University & Hospital
Karachi, Karachi, Pakistan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
E-Da Hospital
Kaohsiung City, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Limited Liability Company "Medical Center Health and Rehabilitation "100 Percent Life"
Poltava, Ukraine
Public Non-Profit Enterprise "Central City Hospital" of Rivne City Council
Rivne, Ukraine
Research Institute of Virology of the Republic of Uzbekistan
Tashkent, Uzbekistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.